Bausch Health Plunges 10.45% Despite Strong Earnings

On March 25, 2025, Bausch Health's stock price dropped by 10.45% in pre-market trading.

Bausch Health reported strong fourth-quarter earnings and revenue, with Xifaxan contributing significantly to sales growth. The company's earnings per share (EPS) for the quarter were $1.21, indicating robust financial performance.

Bausch Health has announced the conditional redemption of its outstanding 5.500% Senior Notes, a move that could impact its financial structure and investor sentiment.

Northwest & Ethical Investments L.P. significantly increased its holdings in Bausch Health, reflecting confidence in the company's future prospects. Similarly, Charles Schwab Investment Management Inc. also boosted its position in the company's shares.